DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwon, Jisoo | ko |
dc.contributor.author | Kim, Taeeun | ko |
dc.contributor.author | Kim, Sun-Mi | ko |
dc.contributor.author | Sung, Heungsup | ko |
dc.contributor.author | Shin, Sung | ko |
dc.contributor.author | Kim, Young Hoon | ko |
dc.contributor.author | Shin, Eui-Cheol | ko |
dc.contributor.author | Kim, Sung-Han | ko |
dc.contributor.author | Han, Duck Jong | ko |
dc.date.accessioned | 2018-01-30T04:22:19Z | - |
dc.date.available | 2018-01-30T04:22:19Z | - |
dc.date.created | 2018-01-08 | - |
dc.date.created | 2018-01-08 | - |
dc.date.issued | 2017-10 | - |
dc.identifier.citation | IMMUNE NETWORK, v.17, no.5, pp.317 - 325 | - |
dc.identifier.issn | 1598-2629 | - |
dc.identifier.uri | http://hdl.handle.net/10203/238840 | - |
dc.description.abstract | Cytomegalovirus (CMV) is one of the most important opportunistic infections in transplant recipients. Tests for CMV-specific T cell responses have been proposed to change the current risk stratification strategy using CMV assays. We evaluated the usefulness of pre-transplant CMV-specific T cell assays in kidney transplant (KT) candidates for predicting the development of CMV infection after transplantation comparing the results of the overlapping peptides (OLPs)-based enzyme-linked immunospot (ELISPOT) assay and the commercial QuantiFERON-CMV assay. We prospectively enrolled all cases of KT over a 5-month period, except donor CMV-seropositive and recipient seronegative transplants that are at highest risk of CMV infection. All the patients underwent QuantiFERON-CMV, CMV OLPs-based pp65, and immediate-early 1 (IE-1)-specific ELISPOT assays before transplantation. The primary outcome was the incidence of CMV infection at 6 months after transplant. The total of 47 KT recipients consisted of 45 living-donor KTs and 2 deceased-donor KTs. There was no association between positive QuantiFERON-CMV results and CMV infection. However, 10 of 34 patients with phosphoprotein 65 (pp65)- or IE-1-specific ELISPOT results higher than cut-off value developed CMV infections compared with none of 13 patients with results lower than cut-off value developed CMV. The OLPs-based ELISPOT assays are more useful than the QuantiFERON-CMV assay for predicting CMV infection. Patients with higher CMV-specific T cell immunity at baseline appear to be more likely to develop CMV infections after KT, suggesting that the abrupt decline in CMV-specific T cell responses after immunosuppression, or high CMV-specific T cell responses due to frequent CMV activation before KT, may promote CMV infection. | - |
dc.language | English | - |
dc.publisher | KOREA ASSOC IMMUNOLOGISTS | - |
dc.subject | T-CELL IMMUNITY | - |
dc.subject | CYTOMEGALOVIRUS VIREMIA | - |
dc.subject | DIAGNOSTIC USEFULNESS | - |
dc.subject | LUNG TRANSPLANTATION | - |
dc.subject | PREGNANT-WOMEN | - |
dc.subject | INCREASED RISK | - |
dc.subject | REACTIVATION | - |
dc.subject | REPLICATION | - |
dc.subject | RESPONSES | - |
dc.subject | THERAPY | - |
dc.title | Comparison of the Commercial QuantiFERON-CMV and Overlapping Peptide-based ELISPOT Assays for Predicting CMV Infection in Kidney Transplant Recipients | - |
dc.type | Article | - |
dc.identifier.wosid | 000418284200006 | - |
dc.identifier.scopusid | 2-s2.0-85033237416 | - |
dc.type.rims | ART | - |
dc.citation.volume | 17 | - |
dc.citation.issue | 5 | - |
dc.citation.beginningpage | 317 | - |
dc.citation.endingpage | 325 | - |
dc.citation.publicationname | IMMUNE NETWORK | - |
dc.identifier.doi | 10.4110/in.2017.17.5.317 | - |
dc.identifier.kciid | ART002278300 | - |
dc.contributor.localauthor | Shin, Eui-Cheol | - |
dc.contributor.nonIdAuthor | Kim, Taeeun | - |
dc.contributor.nonIdAuthor | Kim, Sun-Mi | - |
dc.contributor.nonIdAuthor | Sung, Heungsup | - |
dc.contributor.nonIdAuthor | Shin, Sung | - |
dc.contributor.nonIdAuthor | Kim, Young Hoon | - |
dc.contributor.nonIdAuthor | Kim, Sung-Han | - |
dc.contributor.nonIdAuthor | Han, Duck Jong | - |
dc.description.isOpenAccess | Y | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | Cytomegalovirus | - |
dc.subject.keywordAuthor | Cell-mediated Immunity | - |
dc.subject.keywordAuthor | Enzyme-linked immunospot assay | - |
dc.subject.keywordAuthor | Interferon-gamma Release Test | - |
dc.subject.keywordPlus | T-CELL IMMUNITY | - |
dc.subject.keywordPlus | CYTOMEGALOVIRUS VIREMIA | - |
dc.subject.keywordPlus | DIAGNOSTIC USEFULNESS | - |
dc.subject.keywordPlus | LUNG TRANSPLANTATION | - |
dc.subject.keywordPlus | PREGNANT-WOMEN | - |
dc.subject.keywordPlus | INCREASED RISK | - |
dc.subject.keywordPlus | REACTIVATION | - |
dc.subject.keywordPlus | REPLICATION | - |
dc.subject.keywordPlus | RESPONSES | - |
dc.subject.keywordPlus | THERAPY | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.